Received an FDA 483? Your 48-Hour Response Framework

Your FDA investigator just left the building. On the table is FDA Form 483 — a list of inspectional observations. Your quality team is in crisis mode. What you do in the next 48 hours will determine whether this stays a manageable compliance event or escalates into a Warning Letter, import alert, or consent decree.

Having worked through hundreds of 483 responses over 20 years, the pattern is consistent: companies that respond well share a specific approach. Companies that escalate to Warning Letters almost always make the same predictable mistakes.

First: Understand What a 483 Actually Is

A Form 483 is a list of observations made by an FDA investigator during an inspection. It is not a regulatory action. It is not a finding of violation. It is an opportunity — perhaps the most important compliance opportunity your company will ever receive — to demonstrate to FDA that your quality system is capable of identifying problems and fixing them.

FDA investigators are required to issue a 483 for any condition that in their judgment may constitute a violation of the Food, Drug, and Cosmetic Act. That language — "may constitute" — is significant. It means observations range from clear violations to matters of professional judgment. Not every 483 observation is a crisis. But treating it like one is the right default posture.

The 48-Hour Response Window

While you have 15 business days to submit a formal written response to FDA, the 48 hours after closeout are critical for internal reasons. Use this window to:

• Brief leadership immediately: The CEO, VP Quality/Regulatory, and legal counsel need to be in the room within hours. Do not let the quality department absorb this alone. 483 escalation decisions happen at the senior level.
• Preserve the record: Document exactly what the investigator reviewed, what was said during the inspection, and the context of each observation. Investigator notes and EIR (Establishment Inspection Report) may differ from your recollection — your contemporaneous record is your protection.
• Begin root cause analysis: Not a surface-level corrective action — a genuine root cause investigation. FDA reviewers can tell the difference between a response that identified the root cause and one that described symptoms. The difference determines your risk trajectory.
• Assess your CAPA system's capacity: Can your current CAPA infrastructure absorb the corrective actions this 483 will require? If not, you need to triage and prioritize before drafting your response — not after.

Structuring the Written Response

Your written response to FDA should follow a clear structure for each observation:

• Acknowledgment: You understand the observation and take it seriously — without admitting a regulatory violation if the observation is ambiguous or contested.
• Root Cause: A genuine analysis of what systemic or procedural failure allowed this condition to exist. "Operator error" is almost never an acceptable root cause. FDA expects system-level causes.
• Immediate Correction: What you have already done — not what you plan to do — to address the specific condition observed. Immediate corrections implemented before the response date carry significant weight with FDA reviewers.
• Corrective Action: The systemic change that prevents recurrence. This must address root cause, not just the observed symptom.
• Effectiveness Check: How you will verify that the corrective action works. A CAPA without a defined effectiveness check is a red flag to FDA reviewers.
• Timeline with Completion Dates: Specific, realistic dates. Do not over-promise. FDA tracks whether companies meet their stated commitments — missing your own dates in subsequent inspections damages credibility significantly.

Observations You Should Never Minimize

Some 483 observations require aggressive response regardless of your internal assessment of their severity. These include any observation touching:

• CAPA system deficiencies (21 CFR 820.100)
• Design control failures (21 CFR 820.30)
• MDR reporting gaps (21 CFR Part 803)
• Complaint handling deficiencies (21 CFR 820.198)
• Management responsibility observations (21 CFR 820.20)

Observations in these areas are disproportionately represented in Warning Letters because they signal systemic quality system failure, not isolated procedural gaps. FDA reviewers interpreting your 483 response will weight these heavily.

When to Get External Help

If your 483 contains more than three observations, any observation involving MDR reporting, or any pattern suggesting systemic CAPA or management control failure — engage external regulatory counsel before submitting your response. The cost of a well-structured 483 response is a fraction of the cost of a Warning Letter remediation, import alert response, or consent decree negotiation.

The 483 response is also not the place to argue with FDA's characterization of observations. That argument, if necessary, should happen in a separate regulatory meeting — not embedded in language that could be read as dismissive in a Warning Letter escalation decision.